About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Tennessee | 343 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 343 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 241-260 of 343 trials

TerminatedLGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaThe primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.NCT01820364·Nashville, Tennessee and 5 others CompletedStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaThis is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy…NCT01909453·Birmingham, Alabama and 281 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedPhase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to…NCT01844505·Gilbert, Arizona and 149 others

CompletedAldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryThis randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery.NCT01258855·Duarte, California and 20 others

CompletedRAD001 Plus Bevacizumab in Metastatic MelanomaThis is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.NCT00591734·Fort Myers, Florida and 14 others

TerminatedTovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsThis is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid…NCT07121829·Los Angeles, California and 9 others

TerminatedA Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesThe purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.NCT06974734·Denver, Colorado and 14 others

RecruitingStorage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of TreatmentThe purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.NCT01205815·Nashville, Tennessee

CompletedSafety, Pharmacokinetics (PK) of AKT and MEK CombinationThis study is a Phase 1 dose-escalation open-label study to determine the recommended Phase II dose (RP2D) and regimen for the combination of the orally administered MEK inhibitor…NCT01138085·Aurora, Colorado and 9 others

CompletedA Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or…NCT02752074·Birmingham, Alabama and 128 others

TerminatedSelumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibThis phase II trial studies how well selumetinib and Akt inhibitor MK2206 works in treating patients with stage III or stage IV melanoma who failed prior therapy with vemurafenib…NCT01519427·Atlanta, Georgia and 3 others

RecruitingA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsThis is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.NCT05914116·Tucson, Arizona and 106 others

CompletedAn Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfThis is a study of Nivolumab combined with Ipilimumab followed by Nivolumab by itself for the treatment of patients with Melanoma that has spread to the brain.NCT02320058·Duarte, California and 35 others

UnknownDose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult…NCT03634982·Scottsdale, Arizona and 11 others

RecruitingTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator…NCT05549297·Phoenix, Arizona and 81 others

Active not recruitingA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsThis study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a…NCT03611868·Tucson, Arizona and 20 others

CompletedFirst Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursThe purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination…NCT04504669·Baltimore, Maryland and 12 others

TerminatedA Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid TumorsThis clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and…NCT02605083·Denver, Colorado and 3 others

CompletedEvaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain MetastasesTo assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.NCT00623766·Scottsdale, Arizona and 13 others

CompletedA Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the BrainThis study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF…NCT01266967·Los Angeles, California and 23 others

PreviousPage 13 of 18Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma